Streamlined and Accurate Detection of Actionable Fusions with the oncoReveal Multi-Cancer RNA Fusion v2 Panel
Atrium Health and CPG Pathology compared Pillar's oncoReveal® Multi-Cancer RNA Fusion v2 panel against Archer's FUSIONPlex Pan Solid Tumor v2 for detecting actionable gene fusions in lung and other solid tumors. RNA from 96 fusion-positive specimens — lung, liver, lymph node, brain, sarcoma, pleural and pericardial fluid — was prepared per protocol and sequenced on the Illumina NextSeq 550 Dx with PiVAT® analysis. Pillar detected 82 of 82 covered fusions, fully concordant with Archer, at roughly half the cost per test and with library preparation in 4.5 hours rather than 36.
